Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bradykinin antibodies: new developments.

U Hilgenfeldt1, R Linke, W König

  • 1Department of Pharmacology, University of Heidelberg, F.R.G.

Journal of Cardiovascular Pharmacology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A probabilistic-deterministic approach for assessing climate change effects on infection risks downstream of sewage emissions from CSOs.

Water research·2023
Same author

Automated detection of poor-quality data: case studies in healthcare.

Scientific reports·2021
Same author

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups.

ESMO open·2021
Same author

Pancreas size and exocrine function is decreased in young children with recent-onset Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2019
Same author

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Multiparametric monitoring of microbial faecal pollution reveals the dominance of human contamination along the whole Danube River.

Water research·2017
Same journal

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

Journal of cardiovascular pharmacology·2026
Same journal

A Comprehensive Review of PCSK9 Inhibitor Therapy.

Journal of cardiovascular pharmacology·2026
Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026
Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026
Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026
Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
See all related articles

Researchers developed a specific antibody against bradykinin by linking a modified bradykinin to BSA. This new antibody shows high specificity, requiring both N-terminal and C-terminal residues for recognition.

Area of Science:

  • Immunology
  • Biochemistry
  • Peptide Chemistry

Background:

  • Existing antibodies to bradykinin exhibit cross-reactivity with related peptides.
  • Developing a highly specific antibody is crucial for accurate bradykinin detection and research.

Purpose of the Study:

  • To induce a specific antibody against bradykinin.
  • To characterize the antibody's binding requirements and specificity.

Main Methods:

  • A bradykinin derivative with a Cys residue at position 6 was synthesized.
  • The derivative was conjugated to Bovine Serum Albumin (BSA) using a novel heterobifunctional cross-linking reagent (mal-sac-HNSA).
  • Rabbits were immunized with the conjugate to elicit specific antibodies, followed by cross-reactivity testing.

Related Experiment Videos

Main Results:

  • The induced antiserum demonstrated minimal cross-reactivity with kallidin (4 x 10^-3) and de-Arg1-bradykinin (2 x 10^-4).
  • Antibody recognition was found to require the free N-terminus, as indicated by low cross-reactivity with de-Arg1-bradykinin.
  • Binding affinity was significantly reduced for de-Arg9-de-Phe8-bradykinin (6 x 10^-3), suggesting the importance of C-terminal residues.

Conclusions:

  • The study successfully generated a bradykinin-specific antibody.
  • Antibody recognition is dependent on both the N-terminal and C-terminal residues (phenylalanine and arginine), influenced by bradykinin's ring-like structure.
  • This specific antibody is a valuable tool for precise bradykinin analysis.